PARP-1 inhibition may have a clear benefit in tumour treatment by limiting the rate of cell proliferation and activation of NF-κB, leading to the suppression of both the inflammation and the expression of genes related to tumour progression [69]. The gene discussed is NFKB1; the disease is neoplasm.